# OnCo record nct03407144 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct03407144/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct03407144", "NCT03407144" ;
  schema:name "Safety and Efficacy of Pembrolizumab (MK-3475) in Children and Young Adults With Classical Hodgkin Lymphoma (MK-3475-667/KEYNOTE-667)"@en ;
  schema:alternateName "KEYNOTE 667"@en ;
  schema:description "A phase 2 trial of Pembrolizumab, Doxorubicin, Vinblastine in hodgkin lymphoma, run by Merck Sharp & Dohme LLC, active and no longer recruiting."@en ;
  schema:url <https://onco.cc/trials/nct03407144/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT03407144> ;
  onco:status "active" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2018-04-09" ;
  onco:cancers <https://onco.cc/cancers/hodgkin-lymphoma/>, <https://onco.cc/cancers/early-stage-classical-hodgkin-lymphoma/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/doxorubicin/>, <https://onco.cc/drugs/vinblastine/>, <https://onco.cc/drugs/dacarbazine/>, <https://onco.cc/drugs/cyclophosphamide/>, <https://onco.cc/drugs/vincristine/> ;
  onco:companies <https://onco.cc/companies/merck/> .